• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kras 突变通过激活胰腺癌中的 MEK/ERK 通路促进调节性 T 细胞的转化。

Kras mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.

机构信息

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Pancreatic Cancer Institute, Shanghai, China.

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Shanghai Pancreatic Cancer Institute, Shanghai, China.

出版信息

Cancer Lett. 2019 Apr 1;446:103-111. doi: 10.1016/j.canlet.2019.01.013. Epub 2019 Jan 18.

DOI:10.1016/j.canlet.2019.01.013
PMID:30664964
Abstract

Genetic alterations have been attributed to the abnormal immune microenvironment in cancer. However, the relationship between the Kras mutation and regulatory T cells (Tregs) in pancreatic cancer remains unclear. In this study, we found that Kras mutation status as determined by ddPCR correlated with high levels of Treg infiltration in resectable pancreatic cancer tissues. Compared to wild-type tumour cells, tumours cells with the Kras mutation were associated with higher levels of Tregs, and knockout of the Kras mutation reversed this effect. In addition, overexpression of the Kras mutation in wild-type Kras tumour cells resulted in conversion of CD4CD25 T cells into Tregs. We also found that in tumour cells, the Kras mutation activated the MEK/ERK pathway, thereby up-regulating the levels of interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), which induced Treg conversion. In summary, Kras mutation plays a critical role in Treg conversion and contributes to an immunosuppressive tumour microenvironment in pancreatic cancer. These results provide new insights into the relationship between gene mutation and immune escape.

摘要

遗传改变归因于癌症中异常的免疫微环境。然而,Kras 突变与胰腺癌中的调节性 T 细胞(Tregs)之间的关系尚不清楚。在这项研究中,我们发现,ddPCR 确定的 Kras 突变状态与可切除胰腺癌组织中 Treg 浸润水平升高相关。与野生型肿瘤细胞相比,具有 Kras 突变的肿瘤细胞与更高水平的 Tregs 相关,并且敲除 Kras 突变逆转了这种效应。此外,在野生型 Kras 肿瘤细胞中过表达 Kras 突变导致 CD4CD25 T 细胞转化为 Tregs。我们还发现,在肿瘤细胞中,Kras 突变激活了 MEK/ERK 通路,从而上调白细胞介素 10(IL-10)和转化生长因子-β(TGF-β)的水平,诱导 Treg 转化。总之,Kras 突变在 Treg 转化中起关键作用,并导致胰腺癌中免疫抑制性肿瘤微环境。这些结果为基因突变与免疫逃逸之间的关系提供了新的见解。

相似文献

1
Kras mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.Kras 突变通过激活胰腺癌中的 MEK/ERK 通路促进调节性 T 细胞的转化。
Cancer Lett. 2019 Apr 1;446:103-111. doi: 10.1016/j.canlet.2019.01.013. Epub 2019 Jan 18.
2
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.生长抑素受体亚型 2 缺失通过激活 PI3K 信号和 CXCL16 的过表达促进小鼠 KRAS 诱导的胰腺肿瘤生长。
Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.
3
A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.李斯特菌疫苗和 T 调节细胞耗竭激活针对早期胰腺上皮内瘤变的免疫并延长小鼠的生存时间。
Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.
4
MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.MEK 抑制可防止肿瘤微环境中肿瘤脱落转化生长因子-β诱导的调节性 T 细胞扩增。
Immunology. 2015 Apr;144(4):561-73. doi: 10.1111/imm.12397.
5
Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells.突变 KRAS 将常规 T 细胞转化为调节性 T 细胞。
Cancer Immunol Res. 2016 Apr;4(4):354-65. doi: 10.1158/2326-6066.CIR-15-0241. Epub 2016 Feb 15.
6
Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.Kras 突变与循环调节性 T 细胞相关,可预测晚期胰腺癌患者的预后。
Cancer Med. 2020 Mar;9(6):2153-2159. doi: 10.1002/cam4.2895. Epub 2020 Feb 3.
7
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.髓系细胞是胰腺癌中PD-1/PD-L1检查点激活和免疫抑制环境建立所必需的。
Gut. 2017 Jan;66(1):124-136. doi: 10.1136/gutjnl-2016-312078. Epub 2016 Jul 8.
8
Elevated FBXL6 activates both wild-type KRAS and mutant KRAS and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice.FBXL6 升高可激活野生型 KRAS 和突变型 KRAS,并通过 ERK/mTOR/PRELID2/ROS 轴在小鼠中驱动 HCC 肿瘤发生。
Mil Med Res. 2023 Dec 20;10(1):68. doi: 10.1186/s40779-023-00501-8.
9
Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.激活素受体1B型缺失加速KRAS激活小鼠导管内乳头状黏液性肿瘤的发展。
Gastroenterology. 2016 Jan;150(1):218-228.e12. doi: 10.1053/j.gastro.2015.09.013. Epub 2015 Sep 25.
10
CRISPR/Cas9-Mediated Knock-Out of Kras Mutated Pancreatic Cancer Cell Lines.CRISPR/Cas9 介导的胰腺癌细胞系中 Kras 突变基因敲除。
Int J Mol Sci. 2019 Nov 14;20(22):5706. doi: 10.3390/ijms20225706.

引用本文的文献

1
Domestication and feedback: bidirectional hijacking in pancreatic ductal adenocarcinoma microenvironment.驯化与反馈:胰腺导管腺癌微环境中的双向劫持
Front Immunol. 2025 Aug 11;16:1585858. doi: 10.3389/fimmu.2025.1585858. eCollection 2025.
2
Cancer Vaccination and Immune-Based Approaches in Pancreatic Cancer.胰腺癌的癌症疫苗接种及基于免疫的治疗方法
Cancers (Basel). 2025 Jul 15;17(14):2356. doi: 10.3390/cancers17142356.
3
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?KRAS 突变型癌症中的精准免疫调节:拼图的最后一块?
J Exp Clin Cancer Res. 2025 Jul 3;44(1):189. doi: 10.1186/s13046-025-03444-1.
4
Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers.细胞外囊泡中KRAS反义寡核苷酸(ASO)与维甲酸诱导基因I(RIG-I)激动剂的联合应用可将肿瘤微环境转变为对KRAS依赖性癌症的有效治疗。
Theranostics. 2025 Jun 9;15(14):6818-6838. doi: 10.7150/thno.105519. eCollection 2025.
5
Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.塑造战场:EGFR和KRAS肿瘤突变在肺癌免疫微环境及免疫治疗反应中的作用
Cancer Metastasis Rev. 2025 Jun 17;44(3):56. doi: 10.1007/s10555-025-10272-4.
6
Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.KRAS驱动的肿瘤生态系统的机制基础:整合免疫、代谢、微生物和基质微环境之间的相互作用
Adv Sci (Weinh). 2025 Jun 9:e02714. doi: 10.1002/advs.202502714.
7
Inflammation and cancer: molecular mechanisms and clinical consequences.炎症与癌症:分子机制及临床后果
Front Oncol. 2025 Mar 17;15:1564572. doi: 10.3389/fonc.2025.1564572. eCollection 2025.
8
Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies.探索肺癌微环境:信号通路与基于纳米颗粒的疗法。
Discov Oncol. 2025 Feb 11;16(1):159. doi: 10.1007/s12672-025-01902-y.
9
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.MYC 和 KRAS 合作:癌症治疗机遇中的历史挑战。
Signal Transduct Target Ther. 2024 Aug 21;9(1):205. doi: 10.1038/s41392-024-01907-z.
10
The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer.KRAS表达与结直肠癌中KRAS状态、预后及肿瘤浸润性T淋巴细胞的关系。
Therap Adv Gastroenterol. 2024 May 15;17:17562848241249387. doi: 10.1177/17562848241249387. eCollection 2024.